PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
May 21, 2015
SOUTH PLAINFIELD, N.J., May 21, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the Benefit Assessment by Germany's Federal Joint Committee (G-BA) indicated that Translarna™ (ataluren) provided a benefit for ambulatory patients aged five years and older with nonsense mutation Duchenne Muscular Dystrophy (nmDMD...
May 15, 2015
SOUTH PLAINFIELD, N.J., May 15, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 15, 2015 it approved non-statutory stock options to purchase an aggregate of 112,150 shares of its common stock to 14 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new h...
May 11, 2015
SOUTH PLAINFIELD, N.J., May 11, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced it has launched STRIVE (Strategies to Realize Innovation, Vision and Empowerment), an awards program aimed at providing funds to patient advocacy organizations to develop unique and collaborative programs that will make meaningful contribution...
May 4, 2015
SOUTH PLAINFIELD, N.J., May 4, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2015. "We are off to a strong start this year. In our first full quarter since the commercial launch, we have seen strong support for access to Tra...
Apr 28, 2015
SOUTH PLAINFIELD, N.J., April 28, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that its oncology program targeting BMI1, a protein linked to drug-resistant cancers, has entered a Phase 1 study in patients with advanced solid tumors. The open-label, first-in-human study will investigate the safety and pharmacokinetics ...
Apr 23, 2015
SOUTH PLAINFIELD, N.J., April 23, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Deutsche Bank 40th Annual Health Care Conference, on Wednesday, May 6th  at 10 a.m. ET at The InterContinental Hotel in Boston, MA Bank of America Mer...
Apr 20, 2015
SOUTH PLAINFIELD, N.J., April 20, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2015 financial results on Monday, May 4, 2015 at 4:30 p.m. (ET) after the closing of the market. The call can be accessed by dialing (877) 303-9216 (dome...
Apr 20, 2015
WASHINGTON, April 20, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Phase 1 clinical data from the company's joint development program with Roche and the SMA Foundation in spinal muscular atrophy (SMA) will be presented at the 2015 American Academy of Neurology 67th Annual Meeting. The late-breaking abstract titled...
Apr 10, 2015
SOUTH PLAINFIELD, N.J., April 10, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 7, 2015 it approved non-statutory stock options to purchase an aggregate of 264,200 shares of its common stock to 25 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our ne...
Apr 8, 2015
SOUTH PLAINFIELD, N.J., April 8, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the appointment of Eric Pauwels as Senior Vice President and General Manager Commercial Operations, Americas. Eric will be responsible for the commercial strategy, organizational build out and launch of Translarna in the US, Canada and Latin...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue